Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients

PURPOSE: Idasanutlin is a selective small-molecule MDM2 antagonist. It activates the tumor suppressor TP53 and is in phase 3 clinical trial for acute myeloid leukemia. Nonclinical studies have shown that glucuronidation is the major metabolizing mechanism for idasanutlin and UGT1A3 is the major meta...

Descripción completa

Detalles Bibliográficos
Autores principales: So, W. Venus, Ou Yang, Tai-Hsien, Yang, Xing, Zhi, Jianguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373577/
https://www.ncbi.nlm.nih.gov/pubmed/30511219
http://dx.doi.org/10.1007/s00280-018-3741-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373577/
https://www.ncbi.nlm.nih.gov/pubmed/30511219
http://dx.doi.org/10.1007/s00280-018-3741-2

Ejemplares similares